Drug Trial Radar · NCT00926835
Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
Last checked: Nov 19, 2026Latest source record: Sep 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
692
Actual
Start
May 2009
Primary completion
May 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Ministry of Health & Welfare, KoreaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jun 24, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to investigate the effectiveness of antidepressants on the treatments for non-psychotic major depressive disorder (MDD) in Korea. The study divides MDD patients into 3 level groups according to their past histories to treatments and compares the effectiveness of various treatment regimens at each level. The treatment level groups are: 1) patients who have never been treated with appropriate medications for their current depressive symptoms before, 2) who received an appropriate SSRI (Selective Serotonin Reuptake Inhibitor) once but did not respond to it, 3) who received two types of SSRI antidepressant treatments without much effects in reducing their depressive symptoms. The first level group will be treated with a single SSRI antidepressant treatment. The second and third level groups, who received SSRI treatment before, will be treated with alternative SSRI antidepressants (switching), combined multiple SSRI treatments (antidepressant combination), or SSRI treatments combined with mood stabilizer or anti-psychotics (augmentation). This study does not use placebos. Patients will visit 5 times for 6 weeks at each level for treatments. Patients will be evaluated for the severity of depressive symptoms, functional level, and side effects at each visit. Afterwards, the investigations will combine to monitor the patients depressive symptoms in every 3 months for the next 24 months. 18 nationwide university hospitals will participate in this study. This multi-site, prospective, and naturalistic study for patients with depression in Korea is a main project of 'Clinical Research Center for Depression' funded by the Ministry for Health, Welfare, and Family Affairs (MIHWAF) in Korea for a highly-qualified research achievement.
Conditions
- Major Depressive Disorder
Interventions
paroxetineDrug
6 weeks, 20-50mg/day
EscitalopramDrug
10-20mg/day for 6 weeks
Venlafaxine XRDrug
Venlafaxine 75-225mg/day for 6 weeks
Paroxetine+BupropionDrug
paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
Paroxetine+LamotrigineDrug
Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
Paroxetine+LithiumDrug
Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
Escitalopram+MirtazapineDrug
escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
Escitalopram+AripiprazoleDrug
escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
Paroxetine + Venlafaxine XRDrug
Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hamilton Depression Rating ScaleTime frame: 6 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical research center for depression
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.